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ORIGINAL ARTICLE
Glutathione deﬁcit impairs myelin maturation: relevance for
white matter integrity in schizophrenia patients
A Monin1,2, PS Baumann1,2,3, A Griffa4,5, L Xin6, R Mekle7, M Fournier1,2, C Butticaz1,2, M Klaey1,2, JH Cabungcal1,2, P Steullet1,2,
C Ferrari1,2, M Cuenod1,2, R Gruetter5,6, JP Thiran4,5, P Hagmann4,5, P Conus2,3 and KQ Do1,2
Schizophrenia pathophysiology implies both abnormal redox control and dysconnectivity of the prefrontal cortex, partly related to
oligodendrocyte and myelin impairments. As oligodendrocytes are highly vulnerable to altered redox state, we investigated the
interplay between glutathione and myelin. In control subjects, multimodal brain imaging revealed a positive association between
medial prefrontal glutathione levels and both white matter integrity and resting-state functional connectivity along the cingulum
bundle. In early psychosis patients, only white matter integrity was correlated with glutathione levels. On the other side, in the
prefrontal cortex of peripubertal mice with genetically impaired glutathione synthesis, mature oligodendrocyte numbers, as well as
myelin markers, were decreased. At the molecular levels, under glutathione-deﬁcit conditions induced by short hairpin RNA
targeting the key glutathione synthesis enzyme, oligodendrocyte progenitors showed a decreased proliferation mediated by an
upregulation of Fyn kinase activity, reversed by either the antioxidant N-acetylcysteine or Fyn kinase inhibitors. In addition,
oligodendrocyte maturation was impaired. Interestingly, the regulation of Fyn mRNA and protein expression was also impaired in
ﬁbroblasts of patients deﬁcient in glutathione synthesis. Thus, glutathione and redox regulation have a critical role in myelination
processes and white matter maturation in the prefrontal cortex of rodent and human, a mechanism potentially disrupted in
schizophrenia.
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INTRODUCTION
Abnormalities in functional and structural brain connectivity are
cardinal features of schizophrenia.1 While functional dysconnec-
tivity underlies alterations in neurotransmission system and brain
activity, structural brain dysconnectivity includes impairments in
synapses and myelination processes.1 Recent research has focused
on white matter and factors affecting its integrity. Findings from
transcriptomics,1–3 neuropathology4–6 and neuroimaging1,7–9 pro-
vide compelling evidence for alterations of oligodendrocytes and
myelin in various subregions of the prefrontal cortex including
anterior cingulate cortex of schizophrenia patients. Nevertheless,
the underlying pathophysiological mechanisms are still elusive
and their clariﬁcation would require investigating the early phase
of the disease as their developmental emergence would be
masked by chronicity.
Redox signaling has a key regulating role in many cellular and
physiological processes. A redox dysregulation can affect cell
proliferation/differentiation, energy metabolism and neurotrans-
mission via an alteration of redox-sensitive protein function.10
Converging data indicate a role for redox dysregulation in the
pathophysiology of schizophrenia.11–14 In some studies, decreased
glutathione (GSH) levels, the main cellular non-protein antioxidant
and redox regulator,10,15 have been reported in the cerebrospinal
ﬂuid and prefrontal cortex of patients by using magnetic
resonance spectroscopy (MRS)16,17 and in post-mortem
tissues.14,18 We thus proposed that a redox dysregulation
represents one hub on which converge various causal genetic
and environmental risk factors during neurodevelopment, leading
to structural and functional connectivity impairments. The
genetic vulnerability factors involve either redox regulation genes
directly affecting GSH metabolism,19–22 or genes that indirectly
lead to oxidative stress, including DISC1, PROD, G72, NRG and
DTNBP1.23–27 Environmental factors known to favor major
psychiatric disorders also generate reactive oxygen species
(ROS), which, if the redox regulation is impaired, will perturb the
developing nervous system. As a consequence, two key systems
essential for cognitive and affective functioning will be particularly
affected: local microcircuits and long-range connections. More
speciﬁcally, polymorphisms in the genes coding for the catalytic
(GCLC)20 and modiﬁer (GCLM)22 subunits of the glutamate-
cysteine ligase (GCL), the rate-limiting enzyme for GSH synthesis,
are associated with schizophrenia in case–control studies. The
GAG trinucleotide repeat polymorphisms of GCLC, which are more
frequent in patients (‘GAG high-risk’ genotypes),20 are associated
with changes in plasma thiol levels.28 Compared with the ‘GAG
low-risk’ genotypes, GCL activity and GSH content in ﬁbroblasts
are lower in ‘GAG high-risk’ genotypes under oxidative stress
conditions.20 These data prompted the investigation of GCLM
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knockout mice (GCLM-KO) as a model of schizophrenia. In
developing and adult animals, brain GSH levels are decreased
by 70%,29 and GCLM-KO mice show signs of oxidative stress in
discrete brain regions,29,30 including the anterior cingulate
cortex.30 These mice present behavioral alterations such as
impaired sensory gating, abnormal response to environmental
novelty, and abnormal social and emotion-related behaviors,31 all
known as hallmarks of the disease.
In fact, oligodendrocytes are highly vulnerable to altered redox
state and oxidative stress. They display high metabolic activity and
contain large stores of iron,32 both of which favor ROS production.
Despite that, they contain three times less GSH than astrocytes.32
Oligodendrocytes and their progenitors are particularly sensitive
to hydrogen peroxide15 and nitric oxide inducers.33 GSH deﬁcit
decreases the survival of oligodendrocyte progenitor cells (OPCs)
in vitro.34 In particular, pro-oxidants also modulate oligodendro-
cyte development.35,36
The notion that a redox dysregulation during critical periods of
neurodevelopment could alter structural and functional connec-
tivity has not yet been established. We propose that abnormal
redox control could contribute to the white matter anomalies
observed in schizophrenia. We thus hypothesized that GSH levels
in the medial prefrontal cortex can be involved in the white matter
integrity of the cingulum bundle, a ﬁber tract connecting frontal
brain areas to posterior limbic structures. The ﬁnding of an
association between prefrontal GSH levels and the cingulum white
matter integrity in humans motivated us to study further the
underlying mechanisms in experimental models. The conse-
quences of a GSH deﬁcit on OPCs and myelination during
development were characterized using in vitro and in vivo models,
including GCLM-KO mice.
MATERIALS AND METHODS
Subject recruitment
Patients in the early phase of psychosis, having met the threshold for
psychosis (according to the CAARMS criteria)37 were recruited from the
TIPP Program (Treatment and Early Intervention in Psychosis Program,
University Hospital, Lausanne, Switzerland).38 Normal controls were
recruited and assessed by the Diagnostic Interview for Genetic Studies.39
Major mood, psychotic or substance-use disorder and having a ﬁrst-degree
relative with a psychotic disorder were the exclusion criteria for controls. At
the time of magnetic resonance imaging (MRI) study, 28 patients were
receiving antipsychotic medication, whereas 24 patients were receiving
antipsychotic medication at the time of Fyn study (see Table 1a, Table 1b
and Table 1c for details on demographic information, antipsychotic
medication and chlorpromazine equivalent). Statistical analysis with one-
way analysis of variance did not reveal any signiﬁcant effect of
chlorpromazine equivalents of antipsychotic drugs on GSH, Fyn mRNA
and Fyn protein expression.
Diffusion and functional MRI acquisition and data processing
MRI was performed for all subjects on a 3 T scanner (Trio, Siemens Medical,
Germany) with a 32-channel head coil. Diffusion spectrum imaging (DSI)
was acquired and reconstructed as described in Wedeen et al.40
Speciﬁcally, diffusion-weighted images were sampled in a Cartesian 3D
grid of q-space using 128 diffusion-encoding gradients covering a
hemisphere with b-values varying between 0 and 8000 s mm−2. The
acquisition volume was made of 96× 96× 34 voxels of 2.2 × 2.2 × 3mm3;
TR/TE were, respectively, 6100/144ms. Acquisition time was approximately
13min. In addition, each subject was scanned in resting state conditions
using a standard gradient echo planar imaging sequence sensitive to
blood-oxygen-level-dependent contrast. An axial plane was used with a
matrix of 64 × 58 voxels, each 3.3 × 3.3 mm2. Thirty-two slices of 3.3 mm
Table 1a. Demographic information for control subjects and early
psychosis patients
(a) MRI study
Control subjects
(n= 40)
Patients (n=30) P-value
Age (years± s.d.) 23.5± 3.2 23.1± 3.5 0.7a
Gender 25 men; 15
women
19 men; 11
women
1.0b
Antipsychotic medication (n)
Quetiapine NA 11 NA
Aripiprazole NA 7 NA
Olanzapine NA 4 NA
Amisulpride NA 3 NA
Risperidone NA 2 NA
Paliperidone NA 1 NA
CPZ equivalent
(mg± s.d.)
NA 330.3c± 218.9 NA
Psychosis duration
(years± s.d.)
NA 2.0± 1.8 NA
Abbreviations: CPZ, chlorpromazine equivalents; MRI, magnetic resonance
imaging; n, number of individuals; NA, not applicable. aIndependent
two-tailed Student's t-test. bΧ2 test. cTwo patients without antipsychotic
medication.
Table 1b. Demographic information for control subjects and early psychosis patients
(b) Fyn mRNA study
Control subjects (n= 15) ‘GAG low-risk’ patients (n= 14) ‘GAG high-risk’ patients (n=14) P-valuea
Age (years± s.d.) 25.7± 6.3 23.0± 3.3 23.4± 3.4 0.23
Gender 15 men 14 men 14 men NA
Antipsychotic medication (n)
Quetiapine NA 2 3 NA
Aripiprazole NA 2 2 NA
Olanzapine NA 4 2 NA
Amisulpride NA 3 0 NA
Risperidone NA 1 4 NA
Clozapine NA 1 0 NA
CPZ equivalent (mg± s.d.) NA 358.4b± 197.1 271.8c± 149.9 NA
Abbreviations: ANOVA, analysis of variance; CPZ, chlorpromazine equivalents; n, number of individuals; NA, not applicable. aOne-way ANOVA. bOne patient
without antipsychotic medication. cThree patients without antipsychotic medication.
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thickness with a 0.3 mm gap were acquired. Repetition time was 1920ms,
and acquisition time was 9min.
Furthermore, a magnetization-prepared rapid acquisition gradient
echo sequence was acquired in a matrix of 240× 256× 160 voxels, 1 mm
in-plane resolution and 1.2 mm slice thickness. TR/TI/TE were, respectively,
2300/900/2.98 ms. Acquisition time was approximately 4 min.
DSI, resting state functional MRI (fMRI) and magnetization-prepared
rapid acquisition gradient echo data were processed using the Con-
nectome Mapping Toolkit (http: //www.cmtk.org/)41 and the Connectivity
Decoding Toolkit,42 as described below.
Generalized fractional anisotropy (gFA) in the cingulum bundle. (1) Gray
and white matter were segmented from the magnetization-prepared rapid
acquisition gradient echo acquisition, and the cortical surface was
partitioned into 68 regions of interest with FreeSurfer software (http://
surfer.nmr.mgh.harvard.edu/) according to the Desikan–Killiany atlas.43 (2)
Whole-brain streamline tractography was performed from the DSI using in-
house software.37 (3) Average gFA was extracted along the cingulum
bundle deﬁned as the connections between FreeSurfer regions: medial
orbitofrontal, rostral anterior cingulate, caudal anterior cingulate, posterior
cingulate, isthmus of cingulate and precuneus44 (Figure 1a).
Functional connectivity along the cingulum bundle. (1) fMRI volumes were
preprocessed including motion correction, regression of movement,
average white matter and cerebrospinal ﬂuid signals and linear detrend-
ing. (2) Resting state time series were averaged over the FreeSurfer cortical
regions of interest, and band-pass ﬁltered using the discrete wavelet
transform.42 (3) Functional correlation through the cingulum bundle
was characterized with the Pearson's correlation between the average
low-frequency cortical signals extracted from the medial prefrontal cortex
(covering medial orbitofrontal and superior frontal cortex) on the one
hand, and isthmus of the cingulate cortex and precuneus on the other
hand (Figure 1a).
MRS and data processing
For each individual, MRS experiment was assessed the same day than
diffusion and functional MRI with a time interval of 30 min between the
acquisitions. All MRS experiments were performed with a transverse
electromagnetic volume head coil (MR Instruments, Minneapolis, MN,
USA). The magnetic ﬁeld homogeneity was optimized by adjusting ﬁrst-
and second-order shims using FAST(EST)MAP.45 In vivo proton nuclear
magnetic resonance spectra were acquired from a volume of interest
positioned in the medial bilateral prefrontal lobe using short-TE spin-echo
full-intensity acquired localized single voxel spectroscopy technique.46,47
The following scan parameters were used: volume of interest = 20 × 20 ×
25mm3, TR/TE = 4000/6ms, acquisition bandwidth = 2 kHz, number of
averaged= 148 and vector size = 2048. GSH concentration was obtained
by analyzing water-suppressed in vivo proton nuclear magnetic resonance
spectra using LCModel48 with a basis set consisting of simulated individual
metabolite spectra (Supplementary Figure 1).49 Unsuppressed water
proton nuclear magnetic resonance spectra were used as an internal
reference for the quantiﬁcation of metabolite concentrations. The spectral
range for analysis was set to 0.2–4.2 p.p.m. By using the short-TE MRS
technique at 3T, GSH was quantiﬁed with a Cramer–Rao lower bounds of
7 ± 2% (mean± s.d.).
Fibroblast cell culture and treatment
Fibroblast cell cultures were obtained from skin biopsies using a standard
procedure.22 Cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 2% Ultroser-G serum (Biosepra, Cergy, France),
1 mM sodium pyruvate, 100 Uml− 1 penicillin and 100 μgml− 1 streptomy-
cin. Fibroblasts were plated at 73 cells per mm2. One day after plating, we
treated ﬁbroblasts with 50 μM tert-butylhydroquinone (tBHQ) or vehicle for
18 h. Cells were trypsinized, pelleted and stored at − 80 °C.
Animals
GCLM-KO mice generated by Yang et al.50 were bred, weaned, genotyped
and maintained as described previously.31 All animal procedures were
approved by the Swiss cantonal veterinary ofﬁce.
Oligodendroglial cell culture and lentivirus infection
Mixed glial primary cell cultures were prepared from 1- to 3-day-old Wistar
rat. Cerebral cortices were dissected and dissociated in papain solution
(20 Uml− 1 papain, 100 Uml− 1 DNase and 1mM L-cysteine in L15 medium)
for 30min at 37 °C, followed by mechanic dissociations. Cells derived from
one brain were grown into two poly-L-ornithine-coated 75 cm2 ﬂasks in
DMEM with 10% fetal calf serum and 100 Uml− 1 penicillin–100 μgml− 1
streptomycin. After 7 days, one ﬂask was transduced with lentivirus
containing the scrambled short hairpin RNA (shRNA) and the other with
GCLC shRNA (multiplicity of infection of 5). Puromycin (1 μgml− 1) was
added 2 days after cell transduction for 24 h. This puromycin dose and
time of treatment were normally toxic for non-transduced oligodendrocyte
cells. Transduction efﬁciency was estimated to be495%. OPCs were then
isolated by a method adapted from McCarthy and de Vellis.51 Brieﬂy, ﬂasks
were shaken for 1 h at 37 °C, rinsed two times with DMEM and shaken for
18 h at 37 °C. The supernatant was plated in a plastic dish for 45min, and
then OPCs (supernatants) were plated in poly-L-ornithine-coated coverslips
and maintained in DMEM medium supplemented with 100 Uml− 1
penicillin–100 μgml− 1 streptomycin, 2.5 μM forskolin, 50 μgml− 1 apo-
transferrin, 5 μgml− 1 insulin, 30 nM sodium selenate, 10 nM hydrocortisone,
10 nM D-biotin, 1 mgml− 1 bovine serum albumin, 10 ngml− 1 platelet-
derived growth factor-AA (PDGF-AA) and 10 ngml− 1 basic ﬁbroblast
growth factor (bFGF). In late differentiation experiments, OPCs were grown
in medium lacking growth factors (PDGF-AA and bFGF) and supplemented
with 40 ngml− 1 3,3′,5-triiodo-L-thyronine (thyroid hormone: T3) from
7 days after transduction. OPCs were exposed to 1mM of N-acetylcysteine
(NAC; Sigma, St Louis, MO, USA), or 1 μM 4-amino-5-(methylphenyl)-7-
(t-butyl)pyrazolo-(3,4-d)pyrimidine (PP1) (Fyn inhibitor; Sigma), or to
vehicle for 24 h.
Table 1c. Demographic information for control subjects and early psychosis patients
(c) Fyn protein study
Control subjects (n= 12) ‘GAG low-risk’ patients (n= 10) ‘GAG high-risk’ patients (n=10) P-valuea
Age (years± s.d.) 24.2± 3.1 23.0± 3.7 22.9± 2.8 0.57
Gender 12 men 10 men 10 men NA
Antipsychotic medication (n)
Quetiapine NA 2 2 NA
Aripiprazole NA 1 2 NA
Olanzapine NA 3 1 NA
Amisulpride NA 2 0 NA
Risperidone NA 1 3 NA
Clozapine NA 1 0 NA
CPZ equivalent (mg± s.d.) NA 361.0± 218.2 284.6b± 200.7 NA
Abbreviations: ANOVA, analysis of variance; CPZ, chlorpromazine equivalents; n, number of individuals; NA, not applicable. aOne-way ANOVA. bTwo patients
without antipsychotic medication.
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Antibodies
Antibodies used for immunoﬂuorescent staining were as follows: rabbit
polyclonal anti-NG2 (1:600; Millipore, Temecula, CA, USA), mouse mono-
clonal anti-O4 (1:200; Millipore), mouse monoclonal anti-2′,3′-cyclic-
nucleotide 3'-phosphodiesterase (CNP) (1:500, clone 11-5B; Chemicon,
Temecula, CA, USA), rat monoclonal anti-myelin basic protein (MBP)
(1:400; Millipore), mouse monoclonal anti-APC (CC1; 1:70; Calbiochem,
San Diego, CA, USA), rabbit polyclonal anti-PDGF receptor (PDGFR) (1:350;
Santa Cruz, Santa Cruz, CA, USA), mouse anti-bromodeoxyuridine (BrdU)
(Roche Applied Science, Mannheim, Germany), Cy3 goat anti-mouse IgG
(1:300; Molecular Probes, Eugene, OR, USA), Alexa 488 goat anti-rabbit IgG
or anti-mouse IgG (1:300; Molecular Probes), Cy3 goat anti-rat IgG (1:600;
Millipore) and anti-mouse-Ig-ﬂuorescein (Roche Applied Science).
For western blot experiments, we used mouse antibody to GCLC at
1:10 000 (kindly provided by P Vliet, University of Washington, Seattle, WA,
USA), rabbit polyclonal anti-PDGFR (1:2000; Santa Cruz), mouse
monoclonal anti-Fyn (1:1000; Abcam, Cambridge, UK), mouse mono-
clonal anti-CNP (1:2000; clone 11-5B; Chemicon), mouse monoclonal
anti-α-tubulin (1:200; Santa Cruz), mouse monoclonal anti-β-actin (1:10 000;
Abcam) and horseradish peroxidase-conjugated anti-mouse or anti-rabbit
(1:10 000; GE Healthcare, Buckinghamshire, UK). Mouse monoclonal
antibody to Fyn (Abcam) was used to immunoprecipitate Fyn kinase
protein.
Immunohistochemistry, confocal microscopy and image analysis
Forty- and 90-day-old GCLM-KO mice or wild-type mice were anesthetized,
perfused and their brains were removed as described in Cabungcal et al.52
Brieﬂy, three to six consecutive sections (40 μm) from each animal (bregma
1.14–1.34mm) were selected, permeabilized with 0.3% Triton X-100 in
0.1 M phosphate-buffered saline (PBS) and blocked for 1 h in 0.1 M PBS,
0.3% Triton X-100 and 2% normal goat serum. Sections were incubated for
48 h at 4 °C with the primary antibodies diluted in blocking buffer. After
incubation with secondary antibodies in 0.1 M PBS, 0.3% Triton X-100 for
1 h at room temperature (RT), sections were counterstained with DAPI
(4′-6-diamidino-2-phenylindole: 1.5 μM in 0.1 M PBS; Molecular Probes) for
10min, and were mounted in Mowiol solution. Based on the anatomical
Figure 1. Association between glutathione (GSH) levels in the medial prefrontal cortex and white matter integrity (generalized fractional
anisotropy (gFA)) and functional connectivity along the human cingulum bundle. (a) Representation of the cingulum bundle in green,
illustrating the white matter tract along which the gFA values have been averaged. Red box indicates the volume of interest used for GSH level
measurement. The cingulate cortical regions considered for the evaluation of the functional connectivity through the cingulum are
represented in orange, and include the medial prefrontal cortex, the isthmus of the cingulate cortex and the precuneus. (b and c) Scatter plots
of medial prefrontal GSH levels and both gFA values (top panels) and functional connectivity (bottom panels) along the cingulum bundle in
control subjects (b) and early psychosis patients (c). Each point in the scatter plots represents one subject and red lines represent the
conﬁdence intervals. *Po0.05 with Pearson's correlation and generalized additive model.
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cytoarchitectonic areas given by Franklin and Paxinos,53 the anterior
cingulate cortex (bregma ~ 1.14–1.34) was delineated from the boundaries
of infralimbic and secondary motor cortices, including the cingulate
cortex area 1 (cg1) and part of area 2 (cg2).30 Images were captured with
Zeiss LSM 710 Quasar confocal microscope equipped with a x40 objective
(Zeiss, Göttingen, Germany). Z-stack of 10 images was scanned. As ﬁber
labeling with MBP and CNP was dense, the ﬁrst ﬁve and last ﬁve images
of the z-stack were treated separately. Images were reconstituted with
Imaris 6.2 software (Bitplane, Zürich, Switzerland). In ImageJ (National
Institutes of Health, Bethesda, MD, USA), four areas of 0.02 mm2 were
placed from layer I (Figure 2b). For MBP and CNP quantiﬁcation, a ﬁxed
intensity threshold was applied in each area and ratio of stained pixels
over the total pixel number was calculated. Each value for one area
corresponds to the mean of sum of both z-stack groups. For CC1 or PDGFR
labeling, a ﬁxed intensity threshold was applied in each area and the
number of CC1- or PDGFR-positive cells over 60 pixels was quantiﬁed.
Values reported correspond to the sum of CC1- or PDGFR-positive cells in
all areas.
shRNA construction and lentivirus particle production
GCLM shRNA (5′-CTCAGTCCTTGGAGTTGCAttcaagagaTGCAACTCCAAGGAC
TGAG-3′), GCLC shRNA (5′-GGAGGCTACTTCTATATTAttcaagagaTAATATAG
AAGTAGCCTCC-3′) and scramble shRNA (5′-CTTACAATCAGACTGGCGAttca
agagaTCGCCAGTCTGATTGTAAG-3′) were inserted in a pSP-93 P vector
containing puromycin resistance gene (the nucleotides of the shRNA loop
are indicated by lowercase letters).
Human embryonic kidney 293 T cells were plated and transfected
the day after using calcium phosphate method with the vectors
coding for virion packaging elements (5 μg pMD2.G; 15 μg pCMV-dR8.74)
and vector genome (20 μg shRNA-pSP-93 P). The medium was replaced 8 h
after transfection. Supernatants were collected 24 h later, ﬁltered through
0.45 μm membrane, pelleted at 19 000 r.p.m. for 90min at 4 °C and
resuspended in DMEM. Lentivirus titration was measured with HIV-1 p24
antigen ELISA Kit (ZeptoMetrix, Buffalo, NY, USA).
Monochlorobimane assay
Cells were incubated with 100 μM monochlorobimane (Sigma) in HEPES
buffer (140mM NaCl, 5 mM KCl, 20mM glucose, 2 mM CaCl2, 10 mM HEPES,
1 mM MgCl2, pH 7.4) and ﬂuorescence emission (460 nm) was measured
every minute for 40min under inverted Nikon Eclipse TE300 microscope
equipped with a x20 objective (Nikon, Küsnacht, Switzerland). For
quantiﬁcation in MetaMorph, we selected image captured at 40min and
we subtracted the background. Each value reported corresponds to mean
ﬂuorescence intensity of cells.
Figure 2. Forty-day-old GCLM-KO mice present a decreased immunoreactivity for the myelin-associated protein MBP and the mature
oligodendrocyte marker CC1 in the anterior cingulate cortex. (a) Schematic drawing of coronal section with anterior cingulate cortex included
in the red square, illustrating the region analyzed in panels b–d. (b and c) Confocal images showing MBP labeling in wild-type and GCLM-KO
mice. White boxes represent the region shown in the magniﬁed images in which four different areas (yellow boxes) of 0.02 mm2 were placed
from layer I, and used to quantify MBP labeling in mice, at 40 (b) and 90 days old (c). Scale bar: 50 μm. (d) Quantiﬁcation of MBP-positive pixels
in each delimited area for wild-type (diamond) and GCLM-KO (square) mice, at 40 (red) and 90 days old (black) (n= 6–8 animals per group).
Data are expressed as mean± s.e.m. *Po0.05, analyzed by linear mixed-effect model. (e) Confocal images showing mature oligodendrocytes
labeled with CC1. Scale bar: 50 μm. (f) Quantiﬁcation of CC1-positive cells in area of 0.08 mm2 including layers I–IV (n= 6 animals per group).
Data are expressed as mean± s.e.m. ***Po0.001, analyzed by Student’s t-test. GCLM, gene coding for the modiﬁer subunit of the glutamate-
cysteine ligase; KO, knockout; MBP, myelin basic protein.
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Survival assay
Sytox Orange Nucleic Acid Stain (Invitrogen, Eugene, OR, USA) was added
to cells at 1 μM for 30min at 37 °C before ﬁxation. Nuclei were labeled with
DAPI for 10min and coverslips were mounted in Mowiol solution. Four
images per coverslip were captured with Axioskop2 ﬂuorescence
microscope equipped with a x16 objective (Zeiss). We calculated ratio
between Sytox-positive cell number and total cell number with ImageJ.
Values reported correspond to the mean of ratio from the four images.
Proliferation assay
OPCs were treated with 10 μM BrdU (Roche Applied Science) for 4 h at
37 °C. Cells were ﬁxed, blocked (2% normal goat serum in PBS for 30min)
and immunolabeled following the manufacturer’s instructions. After DAPI
staining, coverslips were mounted in Mowiol solution. Images were
captured using Axioskop2 ﬂuorescence microscope equipped with a x16
objective (Zeiss). We analyzed four images per condition with ImageJ.
Values reported represent the mean of ratio between BrdU- and NG2-
positive cells.
Immunocytochemistry and quantiﬁcation
After ﬁxation, cells were permeabilized with 0.1% Triton X-100 in PBS for
5 min at RT, and blocked in 0.1 M PBS, 2% normal goat serum and 0.1%
Triton X-100 for 30min at RT. Primary antibodies were incubated in PBS,
2% normal goat serum, 0.1% Triton X-100 for 30min at 37 °C. After
incubation with secondary antibodies in PBS for 30min at 37 °C, cells were
counterstained with DAPI for 10min. Coverslips were mounted in Mowiol
solution. Four images per coverslip were captured with Axioskop2
ﬂuorescence microscope equipped with a x40 objective (Zeiss). On each
image, we quantiﬁed the ratio between immunopositive cells and total cell
number using ImageJ.
Western blot
Anterior cingulate cortex from mice was incubated for 10min on ice in
extraction buffer (50mM Tris-HCl (pH 7.5), 250mM NaCl, 1% sodium
dodecyl sulfate, 1 mM dithiothreitol, 1 mM EDTA, 0.01% phenylmethane-
sulfonyl ﬂuoride and protease inhibitor cocktail; Roche, Mannheim,
Germany), sonicated and centrifuged 15min at 10 000 g. OPC pellets were
incubated for 10min in RIPA buffer on ice and centrifuged 15min at
10 000 g. Fibroblast pellets were suspended in ice-cold lysis buffer (50mM
Tris-HCl (pH 7.5), 150mM NaCl, 1 mM EDTA, 1% Triton, 0.1% sodium dodecyl
sulfate, 30 mM sodium ﬂuoride, 1 mM phenylmethanesulfonyl ﬂuoride,
30mM β-glycerophosphate, 0.2 mM sodium orthovanadate and protease
inhibitor cocktail; Roche) and centrifuged 15min at 10 000 g. Proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
on 10% acrylamide gels, and transferred on PVDF membrane (Millipore).
After blocking in Tris-buffered saline (TBS), 0.1% Tween-20 (TBST), 5% milk
for 1 h at RT, membranes were incubated overnight at 4 °C with primary
antibodies diluted in TBST and 3% bovine serum albumin. Membranes
were incubated with horseradish peroxidase-conjugated secondary anti-
body in TBST and 0.5% milk for 1 h at RT. Peroxidase activities were
detected using Amersham ECL Kit (GE Healthcare). Positive signal was
analyzed and normalized to α-tubulin or β-actin with ImageJ.
Immunoprecipitation and Fyn kinase activity
Cell lysates (150 μg) were precleared by incubation with Dynabeads
Protein G (Invitrogen) 30min at 4 °C, before hybridization with 6 μg of Fyn
antibody for 1 h at RT. Complexes were pulled down with 50 μl Dynabeads
Protein G for 30min at RT. After immunoprecipitation, Fyn activity was
measured according to the manufacturer’s protocol (Universal Tyrosine
Kinase Assay Kit; Takara, Shiga, Japan).
RNA isolation and qRT-PCR
RNA were extracted using PerfectPure RNA cultured cell Kit (5Prime,
Hamburg, Germany) or AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Hilden,
Germany) as described in the manufacturer’s protocol. As indicated by the
absorbance ratio 260/280 nm (human samples: 2.08 ± 0.01; animal model
samples: 2.01 ± 0.02; culture samples: 2.10 ± 0.01), RNA were accepted
as pure RNA. cDNA were synthesized using the following reaction mix:
300 ng RNA, 5.5 mM MgCl2, 2 mM dNTP, 0.4 U μl
− 1 RNasin inhibitor, 2.5 μM
random hexamer, 1.25 U μl− 1 RTase and bufferRT 10x from Applied
Biosystem. Taqman real-time PCR was performed in a ﬁnal volume of
20 μl containing 10 ng cDNA, and 1 μl of selected probes mixed with 10 μl
of TaqMan Universal PCR Master Mix (Applied Biosystems). Probes used
were as follows: 18S (4333760 T), Fyn (Hs00941600_m1), p27kip1
(Rn00582195_m1), cyclin D1 (Rn00432360_m1), Rpl27 (Rn00821099_g1),
β-tubulin (Mm00495806_g) and Fyn (Ms00433373_m1). Quantitative PCR
was performed on Applied Biosystems 7500 Fast Real-Time PCR System
and the 7500 Fast System SDS Software as established by the provider
(Applied Biosystems, Foster City, CA, USA). Samples were run in duplicate.
In the animal model, data were normalized to the internal control β-tubulin
and a cerebellum sample. In OPC cultures, data were normalized to mean
between internal control 18S and Rpl27. To prevent ampliﬁcation
ﬂuctuation of the housekeeping gene GAPDH in response to tBHQ
treatment, we normalized human data with 18S, a more stable control
gene. Data were analyzed using ΔΔCt method.54
Statistical analysis
Statistics were performed with R version 2.13. Data from MBP and CNP
immunohistochemistry were analyzed by linear mixed-effect model. In
vitro and in vivo data that followed a normal distribution (veriﬁed by
Shapiro test) were analyzed by paired Student's t-test. Otherwise, a
nonparametric test (Wilcoxon's test) was applied. For multiple comparisons
(control vs NAC or dimethyl sulfoxide (DMSO) vs PP1), we used a linear
mixed-effect model. Antipsychotic drug effect on GSH and Fyn was
analyzed with analysis of variance. Pearson's correlation was used to study
the relationship between GSH and both gFA and functional connectivity in
control subjects. In early psychosis patients, we noticed highly nonlinear
relations between psychosis duration, medication dose and both gFA and
functional connectivity. Consequently, generalized additive model was
used to measure the association between GSH and both gFA and
functional connectivity, allowing a smooth semiparametric relation
between explanatory and response variables without imposing any
parametric relation on the model.
RESULTS
Relationship between frontal GSH levels and connectivity in the
human cingulum bundle
In control subjects and early psychosis patients, we investigated
the relationship between medial prefrontal GSH levels, measured
by proton magnetic resonance spectroscopy, and white matter
integrity in the cingulum bundle, assessed with DSI and the
derived gFA values (Figure 1a).40 In addition, the functional
connectivity along the cingulum (between the medial prefrontal
cortex on one side and the isthmus of the cingulate cortex and
precuneus on the other) was assessed with resting state fMRI
(Figure 1a).55 To focus on the prefrontal maturation period, we
included only individuals younger than 30 years old;56 controls
and patients were matched for age and gender (Table 1a). In
control subjects, signiﬁcant positive correlations between GSH
levels and both gFA values and the functional connectivity along
the cingulum were found (r= 0.34, P= 0.03/r= 0.40, P= 0.01)
(Figure 1b). In early psychosis patients, GSH levels were also
positively associated with gFA values when medication and
psychosis duration were included as covariates (r= 0.31, P= 0.01),
while functional connectivity did not show any correlation with
GSH levels even including these cofactors (r= 0.21, P= 0.34)
(Figure 1c). These ﬁndings indicate a potential dependence
between GSH levels and white matter integrity during the
prefrontal cortex development in control subjects and patients.
Moreover, GSH levels are associated with the functional con-
nectivity in control subjects, a mechanism likely disrupted in
schizophrenia.
GSH deﬁcit affects oligodendrocyte maturation and myelination
To explore the inﬂuence of brain GSH levels on myelination in
the prefrontal cortex (in particular, anterior cingulate cortex;
Figure 2a), we used a mouse model that has low GSH levels
(GCLM-KO). The immunolabeling for two myelin-associated
proteins, CNP and MBP, was decreased in GCLM-KO mice as
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compared with wild-type animals at peripubertal age (CNP: P=0.03;
MBP: P=0.01) (Figures 2b and d and Supplementary Figures 2a and
c) but not in adulthood (Figures 2c and d and Supplementary
Figures 2b and c). Quantiﬁcation revealed a reduction of MBP
immunostaining from the superﬁcial layer to deeper layers in
peripubertal GCLM-KO mice compared with wild-type mice:
45±15% in area a, 63±5% in area b, 41±7% in area c and
35±9% in area d (Figure 2d). Similar results were obtained with CNP
immunolabeling (39±15.3%, 62±6.1%, 43±3.9%, 40±9.1% for
areas a–d, respectively) (Supplementary Figure 2c). We also
quantiﬁed the number of OPCs labeled with PDGFR marker and
the number of mature oligodendrocytes labeled with CC1 marker. At
peripubertal stage, the level of PDGFR-positive cells was similar in
wild-type and GCLM-KO mice (Supplementary Figures 2d and e).
However, the number of CC1-positive cells was reduced by
46.1 ±2.5% in the anterior cingulate cortex of GCLM-KO mice
(P=0.0005) (Figures 2e and f). These observations indicate a critical
role of GSH levels for oligodendrocyte maturation that affects myelin
formation during the peripubertal period.
GSH synthesis deﬁcit impairs proliferation and maturation of OPC
To further investigate the mechanism underlying the effect of redox
dysregulation on oligodendrocyte maturation, we used OPC-
enriched primary cultures (94±0.4% NG2-positive cells) to assess
proliferation and differentiation of OPCs having lower GSH levels
(Figure 3a). Deﬁcit in intracellular GSH was induced by transducing
cells with lentiviral particles containing an shRNA targeting the
catalytic or modulatory subunit of GCL, the rate-limiting enzyme of
GSH synthesis. At 7 days after infection, the GCLC shRNA caused a
49±5% reduction in GCLC subunit as shown by western blot
(P=0.005) (Figure 3b) and a 28±8% decrease in GSH levels
compared with control cells transduced with scrambled sequence
shRNA (P=0.02) (Figure 3c). The GSH decrease induced with GCLC
shRNA remained stable for at least 10 days (P=0.009) (Figure 3c). In
contrast, GCLM shRNA reduced GSH levels only by 15±11% (data
not shown) and thus was not further used. Proliferation of OPCs was
evaluated by BrdU incorporation at 7 days after infection (Figure 3d).
The double staining with BrdU and NG2 indicated that GCLC shRNA
led to a 29±7% reduction in OPC proliferation as compared with
scrambled shRNA (P=0.004) (Figure 3e). In addition, to evaluate the
consequence of GSH deﬁcit on cell cycle, we measured mRNA
expression of p27kip1, an inhibitor of cell cycle, and cyclin D1, a
positive marker for cell cycle progression. No signiﬁcant difference in
p27kip1 expression levels was found between GCLC shRNA samples
as compared with scrambled conditions (P=0.16) (Supplementary
Figure 3a). However, quantiﬁcation of cyclin D1 indicated a
reduction of 19±7% in GCLC shRNA conditions as compared with
scrambled shRNA (P=0.05) (Supplementary Figure 3a). To determine
if the effect was due to an increase in cell death, we assessed
necrosis and apoptosis levels by using Sytox dye. The percentage of
Sytox-positive cells was low and homogenous among groups. In
scrambled conditions, 0.7 ± 0.2% of cells were Sytox positive and
0.8±0.3% were labeled with Sytox in GCLC shRNA conditions
(Supplementary Figures 3b and c). This indicates that a 28% GSH
decrease did not affect OPC survival. NAC, a redox regulator and
GSH precursor, prevented the decrease of proliferation induced by
GSH deﬁcit in GCLC shRNA conditions (Figure 3e), but also increased
OPC proliferation by a factor of 1.7 ± 0.4 (Figure 3e).
Early differentiation of the progenitor cells occurring without
exogenous differentiation factors (thyroid hormone: T3) was also
assessed by immunocytolabeling of stage-speciﬁc markers: O4
for preoligodendrocytes and CNP for oligodendrocytes (Supple-
mentary Figure 4). At 7 days after infection, the density of O4- or
CNP-positive cells was similar in cells transduced with GCLC or
control shRNA (Figure 3f). However, at 10 days after infection, the
proportion of O4- and CNP-positive cells was, respectively,
1.7 ± 0.2 and 2.7 ± 0.3 times higher in conditions with GCLC
shRNA than with the control shRNA (O4: P= 0.05; CNP: P= 0.002)
(Figure 3g). Taken together, this indicates that a GSH deﬁcit may
promote the switch from proliferation to early differentiation.
To evaluate the consequence of GSH deﬁcit on a more mature
oligodendrocyte stage, we cultured OPCs with exogenous
differentiation factors (T3) from 7 days after infection. The level
of CNP protein expression in control and GCLC shRNA OPC
cultures was, respectively, 2.7 ± 0.4 times higher in the differ-
entiating medium (T3) than in the proliferating medium (PDGF-AA,
bFGF) (P= 0.005) (Figure 3h). However, the number of mature
oligodendrocyte labeled with MBP was reduced by 57.2 ± 11% in
GSH-deﬁcit conditions (P= 0.01) (Figures 3i and j).
These observations suggest that a compromised GSH synthesis
decreases proliferation, increases early differentiation of OPCs but
impairs oligodendrocyte maturation in a later stage. We then
explored the molecular mechanism that could link GSH deﬁcit to
the impairment in oligodendrocyte maturation processes.
GSH synthesis deﬁcit affects Fyn kinase
It has been suggested that OPC proliferation may depend on
PDGFR-mediated pathway and the switch from proliferation to early
differentiation is in part due to a Fyn kinase-mediated degradation
of PDGFR.57,58 Therefore, we asked whether an upregulation of Fyn
was responsible for the decreased proliferation in OPCs transduced
with GCLC shRNA. At 7 days after infection, the levels of PDGFR
protein expression were reduced by 16± 5% in GCLC shRNA
compared with scrambled shRNA OPC cultures (P=0.03) (Figure 4a).
While there was no difference in Fyn protein levels between control
and GCLC shRNA OPCs (Figure 4b), a twofold increase in Fyn kinase
activity was observed under GSH-deﬁcit conditions (P=0.04)
(Figure 4c). Inhibition of Fyn with PP1 prevented the decreased
proliferation of OPCs induced by GCLC shRNA (P=0.02) (Figure 4d).
These in vitro results indicate that a GSH deﬁcit leads to a reduction
of OPC proliferation through an increase of Fyn kinase activity that
likely decreases PDGFR protein levels.
Then, we investigated whether an Fyn upregulation was also
present in the anterior cingulate cortex of GCLM-KO mice. Fyn mRNA
expression was increased by 1.2 ±0.05 times in 20-day-old but not
40- and 90-day-old GCLM-KO mice as compared with age-matched
wild-type mice (P=0.04) (Figure 4e). Consistently, Fyn protein levels
were also increased by 1.2 ±0.05 times in 20-day-old GCLM-KO
mice as compared with wild-type mice (P=0.007) (Figure 4f).
These indicate that Fyn is upregulated during the development of
prefrontal cortex in animal model with low GSH levels.
Abnormal Fyn mRNA and protein expression in early psychosis
patient with redox impairments
We then assessed whether abnormal Fyn kinase levels were also
found in early psychosis patients with a redox dysregulation.
We investigated Fyn regulation in response to oxidative stress
induced by tert-butylhydroquinone (tBHQ) in skin-derived ﬁbro-
blasts. In a previous study, we found that under oxidative stress
conditions, GSH levels were signiﬁcantly lower in ﬁbroblasts with
‘GAG high-risk’ compared with ‘GAG low-risk’ GCLC genotypes.20
This and another study on plasma thiol levels indicate that the
‘GAG high-risk’ is associated with impaired redox regulation.28
Here, we compared Fyn mRNA expression in ﬁbroblasts from
control subjects (‘GAG low-risk’) with that of early psychosis
patients (‘GAG low-risk’ and ‘GAG high-risk’ genotypes) (Table 1b).
In absence of tBHQ, Fyn mRNA levels were homogeneous in all
three groups (Figure 4g). The oxidative challenge led to Fyn mRNA
downregulation in ﬁbroblasts from control subjects and ‘GAG low-
risk’ patients, as compared with vehicle treatments (‘GAG low-risk’
control subjects: P= 0.007; ‘GAG low-risk’ patients: P= 0.01)
(Figure 4h). In contrast, no such downregulation was observed
in ﬁbroblasts of ‘GAG high-risk’ genotypes associated with low
GSH levels (Figure 4h). Likewise, Fyn protein levels were
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downregulated in ﬁbroblasts from control subjects and ‘GAG low-
risk’ patients in response to tBHQ treatment (‘GAG low-risk’ control
subjects: P= 3.6e− 06; ‘GAG low-risk’ patients: P= 0.02) (Figure 4i).
However, in ﬁbroblasts of ‘GAG high-risk’ genotypes, Fyn protein
expression was not different in response to oxidative stress
(Figure 4i). In conclusion, ﬁbroblasts from schizophrenia patients
with a genetic risk for an abnormal redox regulation also display
an impaired regulation of Fyn mRNA and protein expressions.
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DISCUSSION
The present study highlights an important role of GSH for
oligodendrocyte differentiation and myelination processes. We
found that GSH levels measured in the medial prefrontal cortex
are positively associated with white matter integrity in the
cingulum bundle of young healthy subjects and early psychosis
patients. In the anterior cingulate cortex of peripubertal GCLM-KO
mice, a constitutive GSH deﬁcit causes reduced expression of
myelin-associated proteins and decreased number of mature
oligodendrocytes. Using OPC cultures, we found that a deﬁcit in
GSH decreases OPC proliferation via Fyn upregulation, and it also
impairs oligodendrocyte maturation. Consistently, ﬁbroblasts of
patients carrying ‘GAG high-risk’ genotypes in the GCLC gene,
which are associated with a phenotype of compromised GSH
synthesis and redox dysregulation, present abnormal regulation of
Fyn when challenged with an oxidative stress.
Our observation that a GSH deﬁcit decreases OPC proliferation
and promotes early differentiation is in agreement with previous
studies showing a switch from OPC division to early differentiation
following treatment with either buthionine sulfoximine (BSO), an
inhibitor of GSH synthesis, or pro-oxidants (i.e. methylmercury,
lead, paraquat) in the absence of differentiating factors in the
medium.57,58 However, when differentiating factors are added to
the medium, a deﬁcit in GSH induced either by GCLC shRNA (this
study) or BSO59 impairs oligodendrocyte maturation. These latter
in vitro data are consistent with the impaired oligodendrocyte and
myelination observed in GCLM-KO mice. Moreover, these data are
further supported by the positive relationship between GSH levels
and gFA along the cingulum bundle in young healthy subjects
and early psychosis patients. This suggests a role for GSH during
the development of ﬁbers, either at the level of myelin or axonal
size or ﬁber packing since gFA can be inﬂuenced by these various
factors.60 Taken together, these suggest that a proper timing of
redox regulation and differentiation signals is crucial to control the
proliferation and the various stages of oligodendrocyte differ-
entiation. Thus, abnormal control of redox system could therefore
affect myelination processes and white matter integrity along
various developmental periods.
Myelination of the prefrontal lobe progresses through adoles-
cence and completes only in early adulthood.61–63 Although the
dynamics of this process may be different in rodents, our
observation that GCLM-KO mice present a myelin deﬁcit in the
anterior cingulate cortex during peripubertal period and no
myelin impairment at adulthood suggests that this latter is a
vulnerable time period during which an adequate redox control is
required. In agreement with this interpretation, a transcriptomic
study in the prefrontal cortex identiﬁed genes for which
expression proﬁles speciﬁcally peak during late adolescence
through early adulthood (i.e. between ages 15 and 25 years).
Besides genes related to either myelin or lipid synthesis, the
antioxidant response system is one of the most highly expressed
during this period.62 In line with this, we found a positive
association between GSH levels and gFA only when individuals
under 30 years of age were included. This corresponds to an age
until which the cingulum bundle is still maturing.56 Early
adulthood coincides with the mean onset of schizophrenia and
the development of higher cognitive processes such as executive
function and social cognitive function,64 both of which are
affected in the disease. We propose that abnormal redox
control during the period of myelin maturation could lead to
disrupted connectivity in the prefrontal cortex and contribute later
in the appearance of the symptoms. Moreover, oligodendrocyte
and myelin impairments may be implicated in cognitive
dysfunction.65,66
In control subjects, GSH levels also positively correlate with the
functional connectivity between the medial prefrontal and the
posterior cingulate cortices in control subjects. Therefore, higher
GSH levels correspond to better synchronization of these two
areas, in line with their higher gFA values.
In the current study, no signiﬁcant difference in prefrontal GSH
levels was observed between patients and control subjects. It
should be noted that the MRS/MRI was performed under ‘resting’
conditions. Indeed, in a previous study with patient-derived
ﬁbroblasts, all patients showed a compromised upregulation of
antioxidant defense as compared with control subjects only under
conditions of challenge by oxidative stress.20 It is thus not
surprising that no signiﬁcant difference in GSH levels was
observed in the current study between patients and control
subjects under ‘resting’ conditions. Furthermore, the absence of
prefrontal GSH level difference may reﬂect a recruitment bias
related to the presently studied small sample. Indeed, an
independent study showed that the ‘GAG high-risk’ genotype of
the GCLC gene predicted lower prefrontal GSH levels.67 In the
genetic association study,20 larger cohorts were investigated and
the ‘GAG high-risk’ genotypes constituted 39% of the patients,
while it is only 20% in the present study, owing to a recruitment
bias of a very demanding study. Summing up, both the ‘resting‘
conditions of MRI and the low proportion of ‘GAG high-risk’
patients in the population investigated explain the absence of
GSH difference between patients and controls.
Finally, our study reveals that a GSH deﬁcit causes an
impairment of Fyn pathway. A GSH deﬁcit results in decreased
Figure 3. Glutathione (GSH) deﬁcit induced by short hairpin RNA (shRNA) against the catalytic subunit (GCLC) of the glutamate-cysteine
ligase reduces proliferation, increases early differentiation but decreases later maturation stage of oligodendrocyte progenitor cells (OPCs).
(a) Oligodendrocyte cell culture immunostained for NG2 (green) and cell nuclei counterstained with 4′-6-diamidino-2-phenylindole (DAPI)
(blue). Scale bar: 50 μm. (b) Quantiﬁcation by western blot of GCLC protein levels in oligodendrocyte cultures treated with either scrambled or
GCLC shRNA. GCLC protein levels were normalized to α-tubulin and expressed as the percentage of their respective scrambled shRNA. Bar
graphs represent mean± s.e.m. (n= 6). **Po0.01. Student’s paired t-test. (c) GSH levels measured after different infection times: 5, 7 or 10 days
(n= 6–7). Values are expressed as the percentage of their respective scrambled shRNA. Bar graphs represent mean± s.e.m. *Po0.05 and
**Po0.01. Student’s paired t-test. (d) Proliferation of OPCs assessed by bromodeoxyuridine (BrdU) incorporation (green) and costained with
NG2 (red) and cell nuclei (DAPI: blue). Scale bar: 50 μm. (e) Effect of N-acetylcysteine (NAC) treatment (24 h) on the number of BrdU-positive
among NG2-positive cells. Data are expressed as the percentage of their respective scrambled shRNA (n= 10, mean± s.e.m.). **Po0.01 and
***Po0.001, analyzed by Wilcoxon's test for control condition and linear mixed-effect model for multiple comparisons (control vs NAC). (f and
g) Quantiﬁcation of O4- and CNP-positive cells over total cell nuclei (DAPI) at 7 (f) and 10 days (g) after infection. Values were expressed as the
percentage of their respective control condition. Bar graphs represent mean± s.e.m. (n= 6–7). *Po0.05 and **Po0.01, analyzed by Student’s
paired t-test. (h) Quantiﬁcation of CNP protein levels in cells treated with either scrambled or GCLC shRNA in either proliferating medium
(platelet-derived growth factor-AA (PDGF-AA), basic ﬁbroblast growth factor (bFGF)) or differentiating medium (T3). CNP protein levels were
normalized to α-tubulin and expressed as the percentage of their respective control condition (PDGF-AA, bFGF). Bar graphs represent
mean± s.e.m. (n= 5). **Po0.01, analyzed by Student’s paired t-test. (i) Representative image of MBP labeling (red) and cell nuclei (DAPI: blue)
in oligodendrocytes expressing scrambled (top panel) or GCLC shRNA (bottom panel) following T3 incubation. Scale bar: 50 μm.
(j) Quantiﬁcation of MBP-positive cells over total cell nuclei after T3 treatment. Values were expressed as the percentage of their respective
scrambled shRNA. Bar graphs represent mean± s.e.m. (n= 6). *Po0.05, analyzed by Student’s paired t-test.
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proliferation in OPC culture via the upregulation of Fyn kinase
activity. Likewise, young GCLM-KO mice have an increase in
Fyn mRNA and protein expressions in the developing anterior
cingulate cortex. The upregulation of Fyn in our in vitro and in vivo
models of GSH deﬁcit is also in line with redox regulation of Fyn
activity described in various cell types, including lymphocytes,
endothelial cells and ﬁbroblasts.68,69 It has been proposed that,
through redox-sensitive sites, oxidative state conditions inactivate
Figure 4. Glutathione (GSH) deﬁcit affects Fyn kinase in rodents and patients. (a) Platelet-derived growth factor receptor (PDGFR) protein
expression was evaluated by western blot at 7 days after infection (n= 7). Protein levels of PDGFR were normalized to α-tubulin and expressed
as the percentage of their respective scrambled short hairpin RNA (shRNA) (black bar). Bar graphs represent means of seven different
experiments± s.e.m. *Po0.05, Student’s paired t-test. (b) Representative western blot of Fyn protein expression at 7 days after infection. (c)
Analysis of Fyn kinase activity. Bar graphs represent Fyn-dependent ATP consumption, expressed as the percentage of the scrambled
condition. Bar graphs represent mean± s.e.m. (n= 5). *Po0.05, Student’s paired t-test. (d) Effect of Fyn inhibitor (4-amino-5-(methylphenyl)-7-
(t-butyl)pyrazolo-(3,4-d)pyrimidine (PP1)) on proliferation assessed by bromodeoxyuridine (BrdU) incorporation. BrdU-positive over NG2-
positive cells were quantiﬁed after 24-h treatment with PP1 at day 7. Data are expressed as the percentage of their respective scrambled
shRNA treated with vehicle (dimethyl sulfoxide (DMSO)) (mean± s.e.m., n= 9). *Po0.05, linear mixed-effect model. (e) Fyn mRNA expression
in the anterior cingulate cortex of wild-type and GCLM-KO mice, at 20, 40 and 90 days old. Data were expressed as mean± s.e.m., relative to
wild-type mice (n= 6–9). *Po0.05, Wilcoxon's test. (f) Quantiﬁcation by western blot of Fyn protein levels in the anterior cingulate cortex of
wild-type and GCLM-KO mice, at 20 days old. Fyn protein levels were normalized to β-actin. Data were expressed as mean± s.e.m., relative to
wild-type mice (n= 6–8). **Po0.01, Student’s t-test. (g) Fyn mRNA expression assessed by quantitative PCR in vehicle condition (DMSO) in
ﬁbroblasts from ‘GAG high-risk’ patients, ‘GAG low-risk’ patients or control individuals. Mean ΔCt value is shown in bar graphs (± s.e.m.). (h)
Fold change in Fyn mRNA expression in ﬁbroblasts following tert-butylhydroquinone (tBHQ) treatment. Mean values of fold change relative to
DMSO treatment (± s.e.m.). *Po0.05 and **Po0.01, Student’s paired t-test or Wilcoxon's test. (i) Fibroblast Fyn protein expression was
analyzed by western blot following tBHQ treatment. Fyn protein expression was normalized by β-actin. Data were expressed as mean± s.e.m.
(n= 10–12), relative to vehicle condition (DMSO). *Po0.05 and ***Po0.001, Student’s paired t-test or Wilcoxon's test.
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protein tyrosine phosphatase leading to the upregulation of the
activity of Src family including Fyn.70 Alternatively, upregulation of
Fyn mRNA expression may be induced by the activation of redox-
sensitive transcription factor Erg1.71 Interestingly, ﬁbroblasts from
early psychosis patients with ‘GAG high-risk’ genotypes, associated
with a vulnerability to redox dysregulation, have impaired
regulation of Fyn mRNA and protein expressions during an
oxidative challenge (tBHQ). Noteworthy, an increase in Fyn mRNA
and protein levels has been also reported in the post-mortem
prefrontal cortex of schizophrenia patients.72 Furthermore, the
Stanley Neuropathology Consortium Integrative Database (a web-
based tool that integrates results of various microarray studies
carried out with the Stanley brain array collection: https://www.
stanleygenomics.org/) reveals a signiﬁcant upregulation of Fyn
mRNA expression in schizophrenia patients (35 cases vs 35
controls). To summarize, the increase of Fyn in a patients’
subgroup may result from an impairment in redox regulation,
and cause impaired Fyn-mediated signaling pathways that could
contribute to developmental abnormalities including oligoden-
drocyte maturation.
Taken all together, these data suggest the presence of a critical
developmental period during which a proper redox regulation
and GSH levels are required for myelination processes. Adverse
events during early life are risk factors for the psychopathology
and myelin development.73,74 This also suggests that there are
several critical periods during which environmental risk factors
could impact the normal development of myelin. Indeed, transient
changes in GSH levels induced by environmental insults during
pre-, peri- and postnatal periods may have an impact on
oligodendrocyte maturation, consequently affecting later struc-
tural connectivity. In addition to schizophrenia, these ﬁndings may
be relevant to other GSH-deﬁcit-related psychiatric disorders,
including bipolar disorder or major depressive disorder, which are
both associated with white matter abnormalities.18,65
A better understanding of molecular mechanisms underlying
redox control of myelination at various developmental vulner-
ability periods will pave the way toward new drug targets and
strategies for the treatment and prevention of schizophrenia.
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